\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes ERC HealthThe European Research Council Executive Agency (ERCEA) currently has two Calls for Expression of Interest open for positions in the Life Sciences domain:
More information in the Call for Expression of Interest. Those interested should send their completed application form to ERC-SELECTION@ec.europa.eu by 31 January 2024 at 12:00 (midday) Brussels time.
More information in the Call for Expression of Interest. Applicants must send their completed applications (CV, Application Form, current contract and declaration on status of employment) to the Permanent Representations, the EFTA Secretariat or the Permanent Delegation of Turkey.
The Permanent Representations, the EFTA Secretariat and the Permanent Delegation of Turkey, must forward the applications to: ERC-SELECTION@ec.europa.eu by 15 February 2024 at 12:00 (midday) Brussels time.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI Continent Deployment: Best use of technologies
The Openverse project hosted last week a high-impact workshop, “National Initiatives and the European Partnership on Virtual Worlds,” aligning stakeholders around the European Commission’s Virtual Worlds strategy. The initiative, rooted in the July 2023 Communication on Web 4.0 and Virtual Worlds, aims to build sustainable, inclus... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
